The SBIR grant could be worth as much as $2.3 million and will help PapGene develop and commercialize its proprietary ovarian and endometrial cancer detection test.
The firm will use the award to develop silica nanomaterial for use with many sample types, including blood, cultured cells, and pathogens.
The company believes it can make oligonucleotide synthesis faster and cheaper than currently available methods, and plans to launch a platform in the next year.
The company is developing a cloud-based platform for the detection, quantification, and interpretation of alternative splicing variation from NGS data.
The technology will allow scientists or clinicians to load crude blood sample and generate DNA sequencing libraries in a fully automated workflow.
The company is developing multiplexed and reverse-phase array versions of its protein phosphorylation-detection technology.
The company aims to use the funding to further optimize the technology and support an ongoing early-access program with beta testers.
The company said the library will be made freely available to academic and non-profit investigators through the DECIPHER Project.
The company aims to launch the qPCR-based test in sub-Saharan Africa.
The products will initially be commercialized for research applications, but the firm hopes to move into diagnostics down the road.
NPR reports that many USDA researchers working at the two agencies that are relocating to the Kansas City area are declining to go.
Genetic genealogy has helped exonerate a man who has been jailed for 20 years, Agence France Presse reports.
A new report says genetically modified food might be necessary to be able to feed a planet of nearly 10 billion people, Bloomberg says.
In Nature this week: new RNA editing approach called LEAPER, draft assembly of Musa balbisiana banana genome, and more.